The benefits of strict glycaemic control in delaying the onset and progression of micro and macrovascular complications in diabetes are undisputed but determining appropriate HbA1c targets remains controversial. This is a particular dilemma when treating patients who have coronary heart disease, particularly the very elderly, many of whom are frail and have several comorbid medical disorders.